| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| NGM-313 | NGM-313; MK-3655 | Phase 2 Clinical | NGM Biopharmaceuticals Inc | Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| JMT-202 | JMT202; JMT-202 | Phase 2 Clinical | Shanghai Jmt-Bio Inc | Hypertriglyceridemia | Details |
| DR-10624 | DR-10624; DR10624 | Phase 2 Clinical | Zhejiang Doer Biologics Corp | Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight | Details |